Abu Sayed

US Patent:

7879544, Feb 1, 2011

Filed:

Jul 29, 2003

Appl. No.:

10/630423

Inventors:

Kiran K. Chada - New York NY, US
Roland Chouinard - Piscataway NJ, US
Hena Ashar - Edison NY, US
Abu Sayed - Cincinnati OH, US

Assignee:

HMGene Inc. - Piscataway NJ

International Classification:

C12Q 1/68
A01K 67/027

US Classification:

435 6, 800 18

Abstract:

Disclosed is a method of identifying genes that are over-expressed in adipose tissue as compared to pre-adipocyte tissue or other tissues comprising performing differential gene expression analysis between the white adipose tissue (WAT) or stromal vascular tissue (SVT) from any two different mice selected from the group consisting of wild-type, HMGI-C −/−, ob/ob, and HMGI-C −/− ob/ob genotype mice. Based on this method a number of nucleotide sequences are identified whose expression is adipocyte specific. The identified nucleotide sequences and their corresponding polypeptides are then used to prevent adipogenesis, to treat diabetes, and to screen for small-molecules that can modulate or prevent adipogenesis and to treat diabetes.

US Patent:

20040259789, Dec 23, 2004

Filed:

Jan 29, 2004

Appl. No.:

10/768566

Inventors:

Kiran Chada - New York NY, US
Roland Chouinard - Piscataway NJ, US
Hena Ashar - Edison NY, US
Abu Sayed - Cincinnati OH, US

International Classification:

A61K038/18

US Classification:

514/012000

Abstract:

Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject. Also disclosed is a screen for molecules that can reduce the amount of adipose tissue in a subject.

US Patent:

20050065092, Mar 24, 2005

Filed:

Jul 22, 2004

Appl. No.:

10/898490

Inventors:

Kiran Chada - New York NY, US
Roland Chouinard - Piscataway NJ, US
Hena Ashar - Edison NY, US
Abu Sayed - Cincinnati OH, US

International Classification:

A61K038/06
A61K038/04

US Classification:

514018000, 514019000, 514423000

Abstract:

Disclosed is a method of using synthetic analogs of natriuretic peptides and more particularly to synthetic linear peptide analogs as pro-lipolytic, as anti-obesity agents, and as intermediates for or modulators of such useful compounds. Inhibitors to nprC are disclosed to treat or prevent adipose accumulation in mammals.

US Patent:

20110288034, Nov 24, 2011

Filed:

Nov 23, 2010

Appl. No.:

12/927750

Inventors:

Kiran K. Chada - New York NY, US
Roland Chouinard - Piscataway NJ, US
Hena Ashar - Edison NY, US
Abu Sayed - Cincinnati OH, US

International Classification:

A61K 38/17
C07H 21/02
C07K 14/435
C07K 16/18
A61P 3/04
C12N 5/10
C12P 21/00
C12Q 1/68
C12Q 1/02
G01N 33/566
C07H 21/04
A61K 31/711

US Classification:

514 212, 536 235, 530350, 5303879, 514 44 R, 435325, 435 691, 435 612, 435 29, 436501

Abstract:

Disclosed is a method of identifying genes that are over-expressed in adipose tissue as compared to pre-adipocyte tissue or other tissues comprising performing differential gene expression analysis between the white adipose tissue (WAT) or stromal vascular tissue (SVT) from any two different mice selected from the group consisting of wild-type, HMGI-C−/−, ob/ob, and HMGI-C−/− ob/ob genotype mice. Based on this method a number of nucleotide sequences are identified whose expression is adipocyte specific. The identified nucleotide sequences and their corresponding polypeptides are then used to prevent adipogenesis, to treat diabetes, and to screen for small-molecules that can modulate or prevent adipogenesis and to treat diabetes.

US Patent:

20130165369, Jun 27, 2013

Filed:

Jun 4, 2012

Appl. No.:

13/487969

Inventors:

Kiran K. Chada - New York NY, US
Roland Chouinard - Piscataway NJ, US
Hena Ashar - Edison NY, US
Abu Sayed - Cincinnati OH, US

International Classification:

A61K 38/17

US Classification:

514 48, 435 612

Abstract:

Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject. Also disclosed is a screen for molecules that can reduce the amount of adipose tissue in a subject.

US Patent:

20160024162, Jan 28, 2016

Filed:

Aug 3, 2015

Appl. No.:

14/816799

Inventors:

Kiran K. Chada - New York NY, US
Roland Chouinard - Piscataway NJ, US
Hena Ashar - Edison NY, US
Abu Sayed - Cincinnati OH, US

Assignee:

HMGENE INC. - PISCATAWAY NJ

International Classification:

C07K 14/47
G01N 33/68
G01N 33/50
C07K 16/18

Abstract:

Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject. Also disclosed is a screen for molecules that can reduce the amount of adipose tissue in a subject.